A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

被引：1
|
作者：
Ross, David M. [1 ]
Arbelaez, Alejandro [2 ]
Chee, Lynette C. Y. [3 ]
Fong, Chun Yew [4 ]
Hiwase, Devendra [5 ]
Kannourakis, George [6 ]
Kwan, John [7 ]
Liang, James [8 ]
Puliyayi, Anish [9 ]
Rose, Hannah [10 ]
Tan, Shuhying [11 ]
Teh, Tse-Chieh [12 ]
esterman, David Alan [13 ]
Wight, Joel
Rovaldi, Chris
Furutani, Elissa M.
Gaggi, Adrienne
Jiang, Ying
Lachey, Jenn
Natarajan, Harveen Dhillon
Ordonez, Claudia
机构：
[1] Flinders Med Ctr & Univ, Dept Haematol, Adelaide, SA, Australia
[2] Tweed Hosp, Brisbane, Qld, Australia
[3] Peter MacCallum Canc Ctr & Royal Melbourne Hosp, Dept Clin Haematol & Bone Marrow Transplant Serv, Melbourne, Vic, Australia
[4] Austin Hlth & Olivia Newton John Canc Res Inst, Dept Clin Haematol, Melbourne, Australia
[5] Royal Adelaide Hosp, Dept Haematol, Adelaide, SA, Australia
[6] Ballarat Onc & Hem Serv, Ballarat, Vic, Australia
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Middlemore Hosp, Auckland, New Zealand
[9] Barwon Hlth, Geelong, Vic, Australia
[10] Box Hill Hosp, Victoria, Australia
[11] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
[12] Townsville Univ Hosp, NS Biopharma Marblehead MA, Townsville, Qld, Australia
[13] Keros Therapeut, Lexington, MA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147335
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3675
引用
收藏
页码：3675 / +
页数：5
相关论文
共 50 条
  • [41] Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response
    Villegas, A.
    Arrizabalaga, B.
    Fernandez-Lago, C.
    Castro, M.
    Mayans, J. R.
    Gonzalez-Porras, J. R.
    Duarte, R. F.
    Remacha, A. F.
    Luno, E.
    Gasquet, J. A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 951 - 960
  • [42] Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study
    Rucker, James
    Butler, Matt
    Hambleton, Sadie
    Bird, Catherine
    Seynaeve, Mathieu
    Cheema, Sanjay
    Campbell-Coker, Kete
    Maggio, Carolina
    Dunbar, Fiona
    Lambru, Giorgio
    Matharu, Manjit
    HEADACHE, 2024, 64 (10): : 1309 - 1317
  • [43] A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
    Alireza Faridar
    Abdulmunaim M. Eid
    Aaron D. Thome
    Weihua Zhao
    David R. Beers
    Maria B. Pascual
    Mohammad O. Nakawah
    Gustavo C. Roman
    Charles S. Davis
    Michael Grundman
    Joseph C. Masdeu
    Stanley H. Appel
    Translational Neurodegeneration, 12
  • [44] Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
    Groen, Kaz
    Stege, Claudia A. M.
    Nasserinejad, Kazem
    de Heer, Koen
    van Kampen, Roel J. W.
    Leys, Rineke B. L.
    Thielen, Noortje
    Westerman, Matthijs
    Wu, Ka-Lung
    Ludwig, Inge
    Issa, Djamila E.
    Velders, Gerjo A.
    Vekemans, Marie-Christiane
    Timmers, Gert-Jan
    de Boer, Fransien
    Tick, Lidwine W.
    Verbrugge, Annelies
    Buitenhuis, Danny
    Cunha, Sonia M.
    van der Spek, Ellen
    de Waal, Esther G. M.
    Sohne, Maaike
    Sonneveld, Pieter
    Nijhof, Inger S.
    Klein, Saskia K.
    van der Donk, Niels W. C. J.
    Levin, Mark-David
    Ypma, Paula F.
    Zweegman, Sonja
    ECLINICALMEDICINE, 2023, 63
  • [45] A RANDOMIZED PHASE-II TRIAL OF LOW-DOSE ACLARUBICIN VS VERY LOW-DOSE CYTOSINE-ARABINOSIDE FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES
    HARADA, M
    SHIBUYA, T
    TESHIMA, T
    MURAKAWA, M
    OKAMURA, T
    NIHO, Y
    GONDO, H
    HAYASHI, S
    AKASHI, K
    TAMURA, K
    MAKINO, S
    NATORI, H
    EGAMI, K
    HISANO, S
    MORIOKA, E
    TANIGUCHI, S
    YAMAZAKI, K
    YAMANO, Y
    OMORI, F
    LEUKEMIA RESEARCH, 1993, 17 (08) : 629 - 632
  • [46] A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease
    Faridar, Alireza
    Eid, Abdulmunaim M.
    Thome, Aaron D.
    Zhao, Weihua
    Beers, David R.
    Pascual, Maria B.
    Nakawah, Mohammad O.
    Roman, Gustavo C.
    Davis, Charles S.
    Grundman, Michael
    Masdeu, Joseph C.
    Appel, Stanley H.
    TRANSLATIONAL NEURODEGENERATION, 2023, 12 (01)
  • [47] Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study
    Eisenchlas, JH
    Garrigue, N
    Junin, M
    De Simone, GG
    PALLIATIVE MEDICINE, 2005, 19 (01) : 71 - 75
  • [48] THE EVALUATION OF LOW-DOSE CYTARABINE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES - A PHASE-III INTERGROUP STUDY
    MILLER, KB
    KYUNGMANN, K
    MORRISON, FS
    WINTER, JN
    BENNETT, JM
    NEIMAN, RS
    HEAD, DR
    CASSILETH, PA
    OCONNELL, MJ
    ANNALS OF HEMATOLOGY, 1992, 65 (04) : 162 - 168
  • [49] Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies
    Glaspy, John
    Gabrail, Nashat Y.
    Locantore-Ford, Patricia
    Lee, Tyson
    Modelska, Katharina
    Samal, Vivek
    Henry, David H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (05) : 703 - 711
  • [50] An open-label study on adding rotigotine treatment to low dose of pramipexole or ropinirole in patients with advanced Parkinson's disease
    Kim, J. M.
    Chung, S. J.
    Kim, J. W.
    Thierfelder, S.
    Bauer, L.
    Jeon, B. S.
    MOVEMENT DISORDERS, 2013, 28 : S220 - S220
12345